This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
This event has ended
The European Society for Medical Oncology (ESMO) 2017 Congress took place on 8–12 September 2017 at Conference Center IFEMA, Madrid, Spain.
Boehringer Ingelheim presented an expert roundtable symposium in thoracic cancers which was chaired by Prof. Silvia Novello and included presentations with panel discussion from Prof. Nicolas Girard, Prof. Shirish Gadgeel and Prof. Sanjay Popat. A post-meeting delayed webcast of the symposium including panel discussions is featured below.
ESMO Symposium Webcast
What factors should be considered in choosing the sequence of EGFR TKIs for EGFR M+ NSCLC patients?
Panel discussion: EGFR TKIs for patients with advanced NSCLC and the importance of overall survival data
EGFR, epidermal growth factor receptor; EGFR M+, epidermal growth factor receptor mutation positive; NSCLC, non small cell lung carcinoma; TKI, tyrosine kinase inhibitor
What is the rationale for use of EGFR TKIs in squamous NSCLC?
Panel discussion: current therapeutic algorithm for squamous NSCLC treatment and considerations for treatment choice
EGFR, epidermal growth factor receptor; NSCLC, non small cell lung carcinoma; TKI, tyrosine kinase inhibitor
What do you think of the anti-angiogenic approach in treating MPM?
Panel discussion: appropriate angiogenic markers, the role of immunotherapy and the potential of oral drugs in MPM
MPM, malignant pleural mesothelioma
Download the symposium slide set below:
Expert roundtable in thoracic cancers: finding our paradigms in an evolving landscape
View this video to see how the landscape for treatment for EGFRM+ NSCLC has evolved, and how insights from afatinib clinical trials can inform treatment sequencing for patients with EGFRM+ NSCLC. The video includes recent data presented at ESMO by Sequist et al.
For more information on afatinib clinical trial data, please click here.
Biomarker prevalence study and Phase I trial of afatinib** in children with malignant tumours
Nysom et al.
Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib* (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)
Novello et al.
Activity of afatinib in heavily pretreated patients (pts) with HER2 mutation-positive (HER2m+) advanced non-small cell lung cancer (NSCLC): findings from a global named patient use (NPU) program
Peters et al.
Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7
Sequist et al.
Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: non-interventional LUME-BioNIS study
Reck et al.
Long-term response to second-line afatinib¶ in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): analysis of the LUX-Head & Neck 1 (LHN1) trial
Machiels et al.
Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial
Font et al.
A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/-endocrine therapy), or non-small-cell lung cancer (NSCLC)
Prat et al.
Didn’t make ESMO 2017? Find out more about upcoming oncology events.
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
**Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.
¶Afatinib is being investigated in urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC) and is not approved for these uses. The efficacy and safety of afatinib in UC and HNSCC have not been established.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue